Immunovant (NASDAQ:IMVT – Get Free Report) and Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Institutional and Insider Ownership
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 5.9% of Immunovant shares are owned by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Immunovant and Jasper Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunovant | N/A | N/A | -$259.34 million | ($2.22) | -11.84 |
| Jasper Therapeutics | N/A | N/A | -$64.46 million | ($4.74) | -4.35 |
Analyst Ratings
This is a breakdown of current recommendations for Immunovant and Jasper Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunovant | 0 | 0 | 10 | 0 | 3.00 |
| Jasper Therapeutics | 0 | 0 | 10 | 0 | 3.00 |
Immunovant presently has a consensus price target of $47.89, suggesting a potential upside of 82.23%. Jasper Therapeutics has a consensus price target of $73.38, suggesting a potential upside of 256.19%. Given Jasper Therapeutics’ higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Immunovant.
Risk and Volatility
Immunovant has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
Profitability
This table compares Immunovant and Jasper Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunovant | N/A | -56.40% | -52.03% |
| Jasper Therapeutics | N/A | -67.64% | -58.53% |
Summary
Jasper Therapeutics beats Immunovant on 5 of the 9 factors compared between the two stocks.
About Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
About Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
